Mirae Asset Global Investments Co. Ltd. Has $728,000 Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Mirae Asset Global Investments Co. Ltd. lessened its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 14.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 31,759 shares of the company’s stock after selling 5,463 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.06% of Protagonist Therapeutics worth $728,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PTGX. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Protagonist Therapeutics by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,473 shares of the company’s stock valued at $25,000 after buying an additional 723 shares during the period. Simplicity Solutions LLC acquired a new position in Protagonist Therapeutics during the third quarter worth $174,000. Teacher Retirement System of Texas boosted its holdings in Protagonist Therapeutics by 6.1% during the third quarter. Teacher Retirement System of Texas now owns 12,954 shares of the company’s stock worth $216,000 after purchasing an additional 740 shares during the last quarter. Obermeyer Wood Investment Counsel Lllp raised its position in Protagonist Therapeutics by 9.4% during the third quarter. Obermeyer Wood Investment Counsel Lllp now owns 13,792 shares of the company’s stock worth $230,000 after acquiring an additional 1,180 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in Protagonist Therapeutics by 7.7% during the third quarter. Principal Financial Group Inc. now owns 14,971 shares of the company’s stock worth $250,000 after acquiring an additional 1,068 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Insider Transactions at Protagonist Therapeutics

In related news, CFO Asif Ali sold 1,234 shares of Protagonist Therapeutics stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the transaction, the chief financial officer now directly owns 37,163 shares of the company’s stock, valued at approximately $933,162.93. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Dinesh V. Ph D. Patel sold 30,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $31.62, for a total transaction of $948,600.00. Following the completion of the transaction, the chief executive officer now directly owns 574,590 shares of the company’s stock, valued at $18,168,535.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Asif Ali sold 1,234 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $25.11, for a total value of $30,985.74. Following the completion of the sale, the chief financial officer now directly owns 37,163 shares of the company’s stock, valued at $933,162.93. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 83,457 shares of company stock worth $2,553,328. Insiders own 5.00% of the company’s stock.

Protagonist Therapeutics Stock Performance

PTGX opened at $25.70 on Thursday. The firm has a market cap of $1.50 billion, a P/E ratio of -17.25 and a beta of 2.01. Protagonist Therapeutics, Inc. has a fifty-two week low of $13.72 and a fifty-two week high of $33.34. The firm has a 50-day moving average of $28.44 and a 200 day moving average of $23.17.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.39. The firm had revenue of $60.00 million during the quarter, compared to analysts’ expectations of $60.00 million. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 1.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on PTGX. JPMorgan Chase & Co. upped their price target on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Protagonist Therapeutics in a report on Wednesday, February 28th. Finally, StockNews.com upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.